-
JAMA Oncol: "The most toxic" breast cancer survival rate increases! Precision Assisted Treatment "Fudan Program" appears in the Journal of the American Medical Association - Oncology
Time of Update: 2020-09-03
results showed that patients receiving the PCb program had a higher five-year disease-free survival rate (86.5 percent vs.
the PCb group had a higher risk of disease-free survival over a five-year period (92.6% vs.
-
Sci Transl Med: "Double-specific antibodies" empower PD-1 to block immunotherapy, stronger and longer-lasting anti-tumor immunity!
Time of Update: 2020-09-03
Immunotherapy, represented by PD-1/PD-L1 blockers, has become an important milestone in the history of cancer treatment, but the limited response rate and primary/secondary resistance of single-drug i
-
JAMA Oncol: The relationship between chemotherapy and survival in elderly breast cancer patients with multiple complications combined with ER-N-plus.
Time of Update: 2020-09-03
Recently, JAMA Oncology published a retrospective study using data from the National Cancer Database (NCDB) to study the relationship between complementary chemotherapy and survival in older patients who were positive for breast and armpit surgery, and those with pathological lymph node-positive leaching breast cancer combined with multiple complications, providing a new basis for treatment decisions in patients with multiple complications combined with old age breast cancer.
-
Immunity: New findings in the field of immunity show how cancer cells evade the immune system.
Time of Update: 2020-09-03
, for cancer therapy, researchers are looking for T-cells in patients who can detect tumor antigens.
To answer this question, the researchers developed a clever way in their experimental model: they attached a marker to genes active in the development of melanoma cells and used them to produce antigens.
-
Cancer Cell: Multi-group analysis helps search for metabolic "breaks" of malignant gliomas
Time of Update: 2020-09-03
results show that blocking alpha-KG produced by Glutamine and Glacose can increase H3K27me3 levels of mutant cells containing H3K27M, thereby inhibiting the growth of DIPG, which carries the mutation.
-
Summary : Will the heart also get tumors? It's not too late to know.
Time of Update: 2020-09-03
according to an analysis of the clinical efficacy of primary heart disease published in the Chinese Journal of Evidence-Based Cardiovascular Medicine in 2020, primary heart disease can achieve good long-term results by surgically removing it in a timely manner.
-
Lancet Oncology: How old is breast cancer screening? The 23-year follow-up data led to discussion.
Time of Update: 2020-09-03
23-year follow-up results, published last week, showed that breast cancer mortality could be significantly reduced by 25 percent in the 10 years before the study, when women were screened annually between the ages of 40 and 49.
-
Amazing! Cell: Blocking TREM2 enhances tumor immunotherapy and completely removes tumors from mouse models.
Time of Update: 2020-09-03
researchers then conducted a study to examine the effects of direct blocking of TREM2 on tumor growth in mice.
analysis of the database suggests that antiTREM2 therapy may be particularly promising in CRC and TNBC because TREM2 expression is negatively associated with the overall survival and recurrence of these cancer patients," the researchers said.
-
Clinical advances in the treatment of bladder cancer.
Time of Update: 2020-09-03
PURE-01 (New Auxiliary Pembrolizumab treatment for myotrophic urethroid bladder cancer; NCT02736266) is a single-arm Phase 2 trial, the first single dose of ICI study under new auxiliary conditions, in which 50 MIBC patients received pembrolizumab.
-
Development Cell: Breast cancer cells use exocystic "dialogue" to hold normal cells hostage.
Time of Update: 2020-09-03
in their study, Altieri's team cultured breast cancer cells in a low-oxygen environment to simulate hypoxia, a hallmark of the micro-environment around most solid tumors, and studied the extracellular follicles (EVs) released by these cells.
-
J Clin Oncol: The effect of valproic acid and valic acid in the treatment of elderly patients with acute myeloid leukemia.
Time of Update: 2020-09-03
We conducted a randomized Phase II trial designed with a 2x2 factor to study the therapeutic effects of histone deacetylase inhibitors valproic acid and full trans-retinal acid (ATRA) on untreated elderly patients with acute myeloid leukemia (AML).
-
NEJM: Effects of advances in lung cancer treatment on mortality.
Time of Update: 2020-09-03
Unlike NSCLC, the mortality rate of non-small cell lung cancer, morbidity and survival rate change SCLC patient mortality rate decreased by the same amount as the morbidity rate, the survival rate of patients did not improve significantly, of which the limited progress of SCLC treatment is the most important factor.
-
Leuk Res: Effect of inojudan anti-treatment of relapse/refractic acute lymphoblastic leukemia patients with minimal residual disease.
Time of Update: 2020-09-03
In the INO-VATE trial, patients with relapsed/refractic acute lymphoblastic leukemia who received Inojudan monotherapy received greater remission and MRD-negative rates than standard chemotherapy, and improved the total survival time: HR was 0.75, and one-sided P was 0.0105.
-
Science: The secret of CD20 monoclonal antibodies to treat B-cell malignancies.
Time of Update: 2020-09-03
the key mechanism difference between type I CD20 monoclonal antibodies (IgG I) and type II (IgG II) is that when combined with CD20, IgG II forms a 1:2 (IgG II:CD20) "end" complex, which prevents the binding of other IgG II.
-
Ultrasound diagnosis of ovarian teratoma.
Time of Update: 2020-09-03
ovarian teratoma is shown as no echo in a single-room tumor, the limitation of the cystic wall is visible thickened and the echo is enhanced.
-
Nano Today: A new strategy for the catalytic treatment of tumors by nanoenzyme pre-drug drugs.
Time of Update: 2020-09-03
Recently, Nano Today published online a research paper by the Institute of Biophysics of the Chinese Academy of Sciences/Chinese Academy of Sciences Nanoenzyme Engineering Laboratory, 'A Metal-Free Nanozyme-Activated Prodrug Strategy for Targeted Tumor Catalytic Therapy'.
-
JAMA Oncol: Relationship between hearing impairment (HI) and neurocognitability in childhood cancer survivors.
Time of Update: 2020-09-02
recently, a cross-sectional study published by American scholars in jama Oncology further analyzed the relationship between hearing sensitivity and task-specific neurocognitive function in the queue of long-term survivors of childhood cancer by treating exposure layering.
-
EXUMA's rPOC platform gives CAR-T cell therapy wings.
Time of Update: 2020-09-02
the above interim results continue to support the company's Conditional Active Biologics (CAB)-CAR-T technology, which is expected to enhance the safety of CAR-T therapeutic drugs in metastatic renal cell carcinoma (mRCC, and hopefully other target-positive solid tumors).
-
Lancet Oncol: Analysis of transcriptional group characteristics associated with the obesity paradox of renal transparent cell carcinoma.
Time of Update: 2020-09-02
Figure 2.COMPARZ (A) and TCGA-KIRC (B) were evaluated using flow cytostomy for primary immune cells in primary tumors of normal weight (7 cases) and obese (16 cases) patients with normal weight with no significant difference in the immune cell population of angiogenic z-score7.
-
Cell: Blood drop detection tumors will become possible! Specificity is more than 90%.
Time of Update: 2020-09-02
published a research paper online at Cell entitled "Extracellular Vesicle and Particle Biomarkers Multiple Define Human Cancers", which looked at the proteomic characteristics of extracellular vesicles and particles (EVPs) in 426 human samples from tissue exosedes (TEs), plasma and other body fluids.
